glp-1 agonists blindness risk Full article: Glucagon-Like Peptide-1 Analogs Associated with a Reduced of Legal in Type 2 Diabetics with Cardiovascular Risks Benefit-Risk Assessment of GLP-1 Receptor
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] 53.Meissner WG, et al
A large body of evidence has demonstrated that complete remission of type 2 diabetes can be achieved by a major weight loss
Differences between GLP1RAs in pharmacokinetics, dosing regimens and clinical effects, including cardiovascular (CV) outcomes, mean there may be benefits to switching from one to another
Data on effectiveness
Because it directly affects appetite and digestion, its metabolic effects extend beyond blood sugar, reaching weight, hunger, and eating behavior
